Yifeng Pharmacy Chain has released its 2026 interim report. Total operating revenue was 12.13 billion yuan, and net profit attributable to the parent company was 964 million yuan. Net cash inflow from operating activities was 1.454 billion yuan, a decrease of 116 million yuan from the same period last year, down 7.40 percent year on year. The company's latest asset-liability ratio was 49.82 percent, gross margin was 40.30 percent, down 0.17 percentage points from the same period last year, and latest return on equity was 7.95 percent. Diluted earnings per share were 0.79 yuan, total asset turnover was 0.46 times, and inventory turnover was 1.66 times. The company had 22,800 shareholders, and the top ten shareholders held 746 million shares, accounting for 61.49 percent of total share capital.
Yifeng PharmacyReports 2026 interim net profit of 964 million yuan, but no comparison to expectations or prior period, so impact unclear.
